NASDAQ: NVCTNuvectis Pharma Inc Stock
$6.18+0.02 (+0.32%)
Updated Sep 6, 2024
NVCT Price
$6.18
Fair Value Price
$1.23
Market Cap
$115.27M
52 Week Low
$5.85
52 Week High
$14.98
P/E
-4.79x
P/B
9.2x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$21.10M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.46
Operating Cash Flow
-$14M
Beta
0.03
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
NVCT Overview
Nuvectis Pharma, Inc. is developing precision treatments for unmet medical needs in oncology. It is using target selection, drug profiling, and clinical and regulatory execution to build a pipeline of anticancer targeted-therapy drugs. The company's lead product candidate, NXP800, targets ovarian clear cell carcinoma (OCCC) and endometrioid ovarian cancer. Nuvectis was incorporated in 2020 and is headquartered in Fort Lee, NJ.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how NVCT scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
NVCT ($6.18) is overvalued by 402.67% relative to our estimate of its Fair Value price of $1.23 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
NVCT ($6.18) is not significantly undervalued (402.67%) relative to our estimate of its Fair Value price of $1.23 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
NVCT is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more NVCT due diligence checks available for Premium users.
Be the first to know about important NVCT news, forecast changes, insider trades & much more!
NVCT News
Valuation
NVCT fair value
Fair Value of NVCT stock based on Discounted Cash Flow (DCF)
Price
$6.18
Fair Value
$1.23
Overvalued by
402.67%
NVCT ($6.18) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
NVCT ($6.18) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
NVCT is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
NVCT price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-4.79x
Industry
-46.85x
Market
24.57x
NVCT price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
9.2x
Industry
6.22x
NVCT is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
NVCT's financial health
Profit margin
Revenue
$0.0
Net Income
-$4.4M
Profit Margin
0%
NVCT's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$18.3M
Liabilities
$5.8M
Debt to equity
0.46
NVCT's short-term assets ($18.30M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
NVCT's short-term assets ($18.30M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
NVCT's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$3.0M
Investing
$0.0
Financing
$1.7M
NVCT's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
NVCT vs Biotech Stocks
Nuvectis Pharma Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.